Novel drug combinations for the management of relapsed/refractory multiple myeloma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue , 2014, Pages S71-S77

  Usmani, Saad Z ^a   Lonial, Sagar ^b  

^a LEVINE CANCER INSTITUTE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Histone deacetylase inhibitors; Immunomodulatory agents; Monoclonal antibodies; Proteasome inhibitors; Treatment

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DARATUMUMAB; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; HOST FACTOR; ISATUXIMAB; LENALIDOMIDE; PANOBINOSTAT; POMALIDOMIDE; PROTEASOME INHIBITOR; RICOLINOSTAT; THALIDOMIDE; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; MONOCLONAL ANTIBODY; OLIGOPEPTIDE;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CHRONIC DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; HUMAN; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; ONCOLOGIST; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; UNITED STATES; ANALOGS AND DERIVATIVES; DISEASE COURSE; DISEASE MANAGEMENT; PATHOLOGY; RECURRENT DISEASE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE MANAGEMENT; DISEASE PROGRESSION; HISTONE DEACETYLASE INHIBITORS; HUMANS; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASOME INHIBITORS; RECURRENCE; THALIDOMIDE;

EID: 84928640823     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.06.016     Document Type: Conference Paper

References (37)

1. S.K. Kumar, S.V. Rajkumar, A. Dispenzieri, and et al. Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2008 2516 2520
2. S.K. Kumar, J.H. Lee, J.J. Lahuerta, and et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study Leukemia 26 2012 149 157
3. Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma [published online August 26, 2013]. Leukemia. http://dx.doi.org/10.1038/leu.2013.247.
4. D.S. Siegel, T. Martin, M. Wang, and et al. A phase 2 study of single agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 120 2012 2817 2825
5. A.J. Jakubowiak, D.S. Siegel, T. Martin, and et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study Leukemia 27 2013 2351 2356
6. M. Wang, T. Martin, W. Bensinger, and et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma Blood 122 2013 3122 3128
7. J.J. Shah, E.A. Stadtmauer, R. Abonour, and et al. Phase I/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma Blood 122 2013 690
8. M.Q. Lacy, and A.R. McCurdy Pomalidomide Blood 122 2013 2305 2309
9. S.A. Schey, P. Fields, J.B. Bartlett, and et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma J Clin Oncol 22 2004 3269 3276
10. M.J. Streetly, K. Gyertson, Y. Daniel, and et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation Br J Haematol 141 2008 41 51
11. M.Q. Lacy, S.R. Hayman, M.A. Gertz, and et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) Leukemia 24 2010 1934 1939
12. P.G. Richardson, D. Siegel, R. Baz, and et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib Blood 121 2013 1961 1967
13. J.S. Miguel, K. Weisel, P. Moreau, and et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial Lancet Oncol 14 2013 1055 1066
14. P.G. Richardson, C.C. Hofmeister, D. Siegel, and et al. MM-005: a phase 1 trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM) Blood 122 2013 1969
15. J. Mikhael, V. Roy, P.G. Richardson, and et al. A phase I/II trial of pomalidomide, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma Blood 122 2013 1940
16. R. Baz, T. Martin, M. Alsina, and et al. Oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone for relapsed and refractory myeloma: report of the dose escalation cohort Blood 122 2013 3200
17. T. Mark, A. Boyer, A.C. Rossi, and et al. ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma Blood 122 2013 1940
18. E.D. Hsi, R. Steinle, B. Balasa, and et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma Clin Cancer Res 14 2008 2775 2784
19. Y.T. Tai, M. Dillon, W. Song, and et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu Blood 112 2008 1329 1337
20. J.A. Zonder, A.F. Mohrbacher, S. Singhal, and et al. A phase I, muliti-center, open-label, dose-escalation study of elotuzumab in patients with advanced multiple myeloma Blood 120 2012 552 559
21. A.J. Jakubowiak, D.M. Benson, W. Bensinger, and et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma J Clin Oncol 30 2012 1960 1965
22. S. Lonial, R. Vij, J.L. Harousseau, and et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma J Clin Oncol 30 2012 1953 1959
23. P.G. Richardson, P. Moreau, A.J. Jakubowiak, and et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: interim results of a phase 2 study Blood 120 2012 202
24. H. Lokhorst, T. Plesner, P. Gimsing, and et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma J Clin Oncol 31 suppl 2013 (abstract 8512)
25. T. Plesner, T. Arkenau, H. Lorkhorst, and et al. Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma Blood 122 2013 1986
26. T.G. Martin, S.A. Strickland, M. Glenn, and et al. SAR650984, A CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies - data from a dose-escalation phase I study Blood 122 2013 284
27. A. Badros, A.M. Burger, S. Phillip, and et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma Clin Cancer Res 15 2009 5250 5257
28. D.M. Weber, T. Graef, M. Hussein, and et al. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma Clin Lymphoma Myeloma Leuk 12 2012 319 324
29. P.G. Richardson, M. Alsina, D. Weber, and et al. PANORAMA 2: panobinostat combined with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma Blood 120 2012 1852
30. J.F. San-Miguel, P. Moreau, S.-S. Yoon, and et al. Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1) J Clin Oncol 30 2012 e18572
31. N. Raje, P.N. Hari, D.T. Vogl, and et al. Rocilinostat (ACY-1215), a selective HDAC6 inhibitor, alone and in combination with bortezomib in multiple myeloma: preliminary results from the first-in-humans phase I/II study Blood 121 2012 4061
32. A. Yee, P. Voorhees, W.I. Bensinger, and et al. ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor, in combination with lenalidomide and dexamethasone (Dex), is well tolerated without dose limiting toxicity (DLT) In patients (pts) with multiple myeloma (MM) at doses demonstrating biologic activity: interim results of a phase 1b trial Blood 122 2013 3190
33. S. Kumar, W.I. Bensinger, T.M. Zimmerman, and et al. Weekly MLN9708, an investigational oral proteasome inhibitor, in relapsed/refractory multiple myeloma: results from a phase I study after full enrollment J Clin Oncol 31 2013 8514
34. I.M. Ghobrial, J.L. Kaufman, D.S. Siegel, and et al. Clinical profile of single-agent modified-release oprozomib tablets in patients (pts) with hematologic malignancies: updated results from a multicenter, open-label, dose escalation phase 1b/2 study Blood 122 2013 3184
35. S. Lonial, J.J. Shah, J. Zonder, and et al. Prolonged survival and improved response rates with ARRY-520 in relapsed/refractory multiple myeloma (RRMM) patients with low α-1 acid glycoprotein (AAG) levels: results from a phase 2 study Blood 122 2013 285
36. A. Chari, M. Hatut, J. Zonder, and et al. A phase 1 study of ARRY-520 with bortezomib (BTZ) and dexamethasone (Dex) in relapsed or refractory multiple myeloma (RRMM) Blood 122 2013 1938
37. J.J. Shah, L. Feng, S.K. Thomas, and et al. Phase 1 study of the novel kinesin spindle protein inhibitor ARRY-520 + carfilzomib (Car) in patients with relapsed and/or refractory multiple myeloma (RRMM) Blood 122 2013 1982